scholarly journals Polymorphism in miR-146a associated with clinical characteristics and outcomes in gastric cancer patients treated with adjuvant oxaliplatin and fluoropyrimidines

2015 ◽  
pp. 2627 ◽  
Author(s):  
Yuqian Liao ◽  
Yu-Lu Liao ◽  
Jun Li ◽  
Li-Xiang Peng ◽  
Yi-Ye Wan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Gastric Cancer Patients

Clinical features, treatments and survival of HER2 positive gastric cancer with elevated alpha-fetoprotein: An analysis of 16 cases.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16000-e16000
Author(s):  
Shaohua Ge ◽  
Yi Ba ◽  
Ting Deng ◽  
Yuchong Yang ◽  
Tao Ning ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Clinical Characteristics ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Elevated Serum ◽  
Her2 Positive ◽  
The Mean ◽  
Gastric Cancer Patients

e16000 Background: Gastric cancer with elevated alpha-fetoprotein (AFP) is a special type of gastric cancer with elevated serum AFP. It is often misdiagnosed as primary hepatic cancer due to abnormal AFP and liver metastasis. The AFP level is related to the prognosis of these patients in whom there is prone to high HER2 positive rate. Therefore, anti-HER2 treatment is optional, as well as the emerging immunotherapy with immune checkpoint inhibitors. Methods: Gastric cancer patients with HER2 and serum AFP examination were collected in our hospital from May 2017 till now. Serum AFP level over 7 ng/ml was defined as elevated AFP. The clinical characteristics, treatments and survival of the patients with HER2 positive and elevated AFP were picked and analyzed. Results: Among 135 gastric cancer patients with elevated AFP, 16 (11.9%) were HER-2 positive (12 with HER2 3+, 3 with HER2 2+/FISH+ and 1 with HER2 gene amplification in NGS). The mean serum AFP is 201.4± 476.7ng/ml (range: 7.74 -1335). There were 9 males and 7 females. The mean age was 55 years (range: 38-90). The tumors were located in stomach cardia and fundus in 5 cases, body in 5 cases, antrum in 4 cases, body and antrum in 1 case and whole stomach in 1 case. There were 2 patients in stage III and 14 patients in stage IV with metastasis to lymph node metastasis in 15, liver in 9, abdominal cavity in 3 and peritoneum in 3. As for the treatments, three patients underwent surgery, one of whom with exploratory laparotomy (no antitumor treatment after surgery, died from infection). In 13 advanced patients, 12 patients received systemic antitumor therapies (8 with chemotherapy+Trastuzumab+ immunotherapy, 2 with chemotherapy+Trastuzumab, 1 with chemotherapy+ immunotherapy and 1 with chemotherapy). The chemotherapy regimens were XELOX in 5 cases, SOX in 4 cases and FLOT in 2 cases. The response rate was 50% (6 in 12 patients) and the disease control rate was 100%. The median PFS was 7.5 months in first line therapy with six patients without progression disease yet. The longest PFS with PR lasted for 16.5 months with chemotherapy, trastuzumab and immune checkpoint inhibitor. Conclusions: Gastric cancer with HER2 positive and elevated serum AFP is a disease with special clinical characteristics. Patients with advanced diseases can be treated with chemotherapy, trastuzumab +/- immune checkpoint inhibitors. This combination is expected to become a new regimen to improve survival of such special patients.

scholarly journals Clinical Characteristics and Outcomes of Gastric Cancer Patients Aged over 80 Years: A Retrospective Case-Control Study

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0167615 ◽  
Author(s):  
Hee Jung Park ◽  
Ji Yong Ahn ◽  
Hwoon-Yong Jung ◽  
Jeong Hoon Lee ◽  
Kee Wook Jung ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Case Control Study ◽  
Case Control ◽  
Retrospective Case ◽  
Gastric Cancer Patients ◽  
Control Study

Clinical characteristics and outcomes for gastric cancer patients aged 18–30 years

2014 ◽  
Vol 17 (4) ◽  
pp. 649-660 ◽  
Author(s):  
Hee Jung Park ◽  
Ji Yong Ahn ◽  
Hwoon-Yong Jung ◽  
Hyun Lim ◽  
Jeong Hoon Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Gastric Cancer Patients

scholarly journals Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review

2020 ◽  
Vol Volume 13 ◽  
pp. 11637-11644
Author(s):  
Naama Halpern ◽  
Albert Grinshpun ◽  
Ben Boursi ◽  
Talia Golan ◽  
Ofer Margalit ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Literature Review ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Germline Mutations ◽  
Brca 1 ◽  
Gastric Cancer Patients

scholarly journals GBP1 Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Gastric Cancer

2021 ◽  
Author(s):  
Xiaoqiang Feng ◽  
Zedan Zhang ◽  
Qingke Chen ◽  
Chujin Ye ◽  
Tong Tan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
T Cells ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Prognostic Biomarker ◽  
Gene Marker ◽  
M2 Macrophage ◽  
Normal Tissues ◽  
Gastric Cancer Patients ◽  
The Relationship

Abstract Background: The guanylate-binding protein 1 (GBP1) belongs to the member of GTPase dynamin superfamily and plays a major role as tumor suppressor or tumorigen in cancers, such as colon cancer, ovarian cancer, melanoma, and head and neck squamous cell carcinoma. However, the relationship between GBP1 and gastric cancer (GC) remains scanty. Methods: GBP1 mRNA expression in different types of tumors and their corresponding adjacent normal tissues were evaluated via exploring Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA) database, while the protein expression was detected by The Human Protein Atlas (HPA). The relationship between the clinical characteristics and outcome of gastric cancer patients was examined through Kaplan–Meier plotter tool. The correlations between GBP1 and tumor immune infiltrates were evaluated via TIMER and TISIDB. Additionally, the relationship between GBP1 expression and gene marker sets of immune infiltrates were analyzed by TIMER and GEPIA.Results: GBP1 expression was significantly higher in GC compared with corresponding normal tissues. High GBP1 expression in GC associated with better overall survival (OS HR=0.53, P=5.2e-09) and progression-free survival (PFS HR=0.49, P=1.90e-06). Moreover, its expression level was positively correlated with different clinical characteristics, such as sex, TNM stage, and Lauren classification. With a comprehensive analysis of three immune-related databases, TIMER, GEPIA, and TISIDB, we found GBP1 not only showed a strong correlation with tumor-infiltrating CD8+ T cells, Th1 cells, but also with Tregs, exhausted T cells, M2 macrophage, monocytes. Furthermore, GBP1 was significantly associated with IFN-γ, granzyme B, perforin, FasL and CXCL9, CXCL10, and CXCL11. Conclusion: This study provides the first evidence that GBP1 is a key gene that correlates with the prognosis and associated with various tumor-infiltrated immune cells in gastric cancer patients. In conclusion, GBP1 may act as a potent prognostic biomarker for predicting cancer progression and a sign of tumor-immune infiltration in GC.

scholarly journals Demographic and clinical characteristics of gastric cancer patients in north of Iran, Mazandaran province, 2008-2014

2015 ◽  
Vol 1 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Seyed Khalil Mousavi ◽  
Ghasem Janbabai ◽  
Bizhan Kouchaki ◽  
Hanieh Borhani ◽  
Masoumeh Rashidi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Characteristics ◽  
Mazandaran Province ◽  
North Of Iran ◽  
Gastric Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document